ClinicalTrials.Veeva

Menu
N

National Taiwan University Hospital | Department of Internal Medicine, Division of Gastroenterology

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Budigalimab
Livmoniplimab

Parent organization

This site is a part of National Taiwan University Hospital

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

1 of 1 total trial

A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC) (LIVIGNO-2)

Hepatocellular carcinoma (HCC) is a common cancer worldwide and a leading cause of cancer-related death. The majority of participants first presentin...

Enrolling
Hepatocellular Carcinoma
Drug: Budigalimab
Drug: Durvalumab

Trial sponsors

AbbVie logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems